Skip to content
  • Home
  • Technology
    • The platform
    • Artificial Intelligence
    • BioClick
    • Nobel Prize heritage
    • Biosolution phases
    • Scientific papers
    • Patents
  • Pipeline
    • Pipeline overview
    • NCT: Over-the-Counter
    • NCT: Pharma
    • Cannabinoids
    • Santalene
    • Become a partner
  • Investors
    • Stock information
    • News
    • Email signup
    • Investor Relation Contacts
    • Governance
    • SEC Filings
    • Video
  • About
    • Leadership team
    • History
    • Jobs
    • Policies
    • Contact
  • News
    • Latest news
    • Media coverage
    • Investor news
    • News archive
Homepage
Open navigation
  • Home
  • Technology
    • The platform
    • Artificial Intelligence
    • BioClick
    • Nobel Prize heritage
    • Biosolution phases
    • Scientific papers
    • Patents
  • Pipeline
    • Pipeline overview
    • NCT: Over-the-Counter
    • NCT: Pharma
    • Cannabinoids
    • Santalene
    • Become a partner
  • Investors
    • Stock information
    • News
    • Email signup
    • Investor Relation Contacts
    • Governance
    • SEC Filings
    • Video
  • About
    • Leadership team
    • History
    • Jobs
    • Policies
    • Contact
  • News
    • Latest news
    • Media coverage
    • Investor news
    • News archive

Posts in: press release (3)

eXoZymes to Host Fourth Quarter and Full Year 2024 Results Conference Call on Wednesday April 2, 2025
press releaseIPOinvestor
eXoZymes to Host Fourth Quarter and Full Year 2024 Results Conference Call on Wednesday April 2, 2025March 26, 2025
Edgardo Rayo, new member of the Board of Directors at eXoZymes Inc.
press releaseinvestor
eXoZymes and MDB Capital Announce Leadership Transition at eXoZymes Inc.February 21, 2025
eXoZymes Announces Nasdaq Bell Ringing to Commemorate Initial Public Offering on Feb 19, 2025
press releaseIPOinvestor
Nasdaq Bell Ringing to Commemorate Initial Public OfferingFebruary 19, 2025
Rebranding Invizyne to eXoZymes signifies a sustainable paradigm shift in chemical production leveraging AI-engineered enzymes
press releaseinvestor
Rebranding Invizyne to eXoZymes signifies a sustainable paradigm shift in chemical production leveraging AI-engineered enzymesFebruary 12, 2025
Invizyne Technologies Announces Name Change to eXoZymes, Inc. and New Ticker Symbol
press releaseinvestor
Invizyne Technologies Announces Name Change to eXoZymes, Inc. and New Ticker SymbolFebruary 10, 2025
ARCHIVE: Invizyne Technologies Selected for $2 Million Project to Advance Sustainable Aviation Fuel Capabilities
biofuelpress releaseARCHIVE
ARCHIVE: Invizyne Technologies Selected for $2 Million Project to Advance Sustainable Aviation Fuel CapabilitiesNovember 19, 2024
ARCHIVE: Invizyne Technologies Announces Closing of Initial Public Offering
press releaseinvestorARCHIVE
ARCHIVE: Invizyne Technologies Announces Closing of Initial Public OfferingNovember 14, 2024
ARCHIVE: Invizyne’s Nasdaq IPO Marks New Era of Biomanufacturing
press releaseinvestorvideoARCHIVE
ARCHIVE: Invizyne’s Nasdaq IPO Marks New Era of BiomanufacturingNovember 13, 2024
ARCHIVE: Invizyne Technologies Begins Trading on NASDAQ
press releaseinvestorARCHIVE
ARCHIVE: Invizyne Technologies Begins Trading on NASDAQNovember 13, 2024
ARCHIVE: Invizyne Technologies to Begin Trading on NASDAQ on November 13, 2024
press releaseinvestorARCHIVE
ARCHIVE: Invizyne Technologies to Begin Trading on NASDAQ on November 13, 2024November 12, 2024
Previous page
Page 3 of 4
Next page

eXoZymes Inc.

750 Royal Oaks Dr, st 106, 
Monrovia 91016, CA, USA

P: (626) 415-1488
E: info@exozymes.com

 

© eXoZymes Inc. [Nasdaq:EXOZ] unshackling enzymes since 2019 (formerly known as Invizyne Technologies)

logo mark